What does this research mean for the field?

Liancao Xueniao Capsule alleviates podocyte injury and improves hematuria in IgA nephropathy by suppressing the TNF-mediated inflammatory signaling pathway. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To investigate the molecular mechanisms through which Liancao Xueniao Capsule mitigates hematuria and renal damage in IgA nephropathy.

August 30, 2026Journal of Visualized Experiments

Mechanisms of Liancao Xueniao Capsules in Treating Hematuria Associated with IgA Nephropathy: Network Pharmacology and Experimental Validation

View Full Paper

Ask AI

Bookmark

Authors

HWHongan WangThe Affiliated Hospital to Changchun University of Chinese Medicine FLFan LiThe Affiliated Hospital to Changchun University of Chinese Medicine YZYibin ZhangThe Affiliated Hospital to Changchun University of Chinese Medicine

Discussion

Member takes

Implication

Preclinical study reveals that Liancao Xueniao Capsule reduces hematuria and podocyte damage in IgA nephropathy rats, indicating therapeutic benefit via TNF pathway suppression.

Key Points

To investigate the molecular mechanisms through which Liancao Xueniao Capsule mitigates hematuria and renal damage in IgA nephropathy.
Integrated network pharmacology analysis with an in vivo experimental model of IgA nephropathy in rats.
Administered Liancao Xueniao Capsule over an 8-week treatment period and assessed renal function, histopathology, and inflammatory pathway markers.
Treatment significantly reduced urinary erythrocytes, 24-hour urinary albumin, serum creatinine, and blood urea nitrogen while ameliorating renal pathological injury and fibrosis.
Capsule administration restored the expression of podocyte-specific proteins CD2AP and WT-1 and markedly decreased pro-inflammatory cytokines TNF-α, IL-1β, and IL-6.
Renal protective effects were mediated by the targeted suppression of the TNF signaling pathway and its downstream effectors.

Cite This Study

Wang et al. (2026) studied this question.

synapsesocial.com/papers/6a93f0696c1a8fb52e79c87e https://doi.org/10.3791/71582

View Full Paper

Ask AI

Bookmark

Implication

Preclinical study reveals that Liancao Xueniao Capsule reduces hematuria and podocyte damage in IgA nephropathy rats, indicating therapeutic benefit via TNF pathway suppression.

Mechanisms of Liancao Xueniao Capsules in Treating Hematuria Associated with IgA Nephropathy: Network Pharmacology and Experimental Validation

Discussion

Member takes

Implication

Key Points

Cite This Study

Mechanisms of Liancao Xueniao Capsules in Treating Hematuria Associated with IgA Nephropathy: Network Pharmacology and Experimental Validation

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider